Literature DB >> 18645010

Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase.

Tatiana Okouneva1, Olga Azarenko, Leslie Wilson, Bruce A Littlefield, Mary Ann Jordan.   

Abstract

Eribulin (E7389), a synthetic analogue of halichondrin B in phase III clinical trials for breast cancer, binds to tubulin and microtubules. At low concentrations, it suppresses the growth phase of microtubule dynamic instability in interphase cells, arrests mitosis, and induces apoptosis, suggesting that suppression of spindle microtubule dynamics induces mitotic arrest. To further test this hypothesis, we measured the effects of eribulin on dynamics of centromeres and their attached kinetochore microtubules by time-lapse confocal microscopy in living mitotic U-2 OS human osteosarcoma cells. Green fluorescent protein-labeled centromere-binding protein B marked centromeres and kinetochore-microtubule plus-ends. In control cells, sister chromatid centromere pairs alternated under tension between increasing and decreasing separation (stretching and relaxing). Eribulin suppressed centromere dynamics at concentrations that arrest mitosis. At 60 nmol/L eribulin (2 x mitotic IC(50)), the relaxation rate was suppressed 21%, the time spent paused increased 67%, and dynamicity decreased 35% (but without reduction in mean centromere separation), indicating that eribulin decreased normal microtubule-dependent spindle tension at the kinetochores, preventing the signal for mitotic checkpoint passage. We also examined a more potent, but in tumors less efficacious antiproliferative halichondrin derivative, ER-076349. At 2 x IC(50) (4 nmol/L), mitotic arrest also occurred in concert with suppressed centromere dynamics. Although media IC(50) values differed 15-fold between the two compounds, the intracellular concentrations were similar, indicating more extensive relative uptake of ER-076349 into cells compared with eribulin. The strong correlation between suppression of kinetochore-microtubule dynamics and mitotic arrest indicates that the primary mechanism by which eribulin blocks mitosis is suppression of spindle microtubule dynamics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18645010      PMCID: PMC2562299          DOI: 10.1158/1535-7163.MCT-08-0095

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  24 in total

1.  Mammalian mad2 and bub1/bubR1 recognize distinct spindle-attachment and kinetochore-tension checkpoints.

Authors:  D A Skoufias; P R Andreassen; F B Lacroix; L Wilson; R L Margolis
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest.

Authors:  Kathy Kamath; Mary Ann Jordan
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

3.  Suppression of centromere dynamics by Taxol in living osteosarcoma cells.

Authors:  Jonathan Kelling; Kevin Sullivan; Leslie Wilson; Mary Ann Jordan
Journal:  Cancer Res       Date:  2003-06-01       Impact factor: 12.701

4.  Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin.

Authors:  Donnette A Dabydeen; James C Burnett; Ruoli Bai; Pascal Verdier-Pinard; Sarah J H Hickford; George R Pettit; John W Blunt; Murray H G Munro; Rick Gussio; Ernest Hamel
Journal:  Mol Pharmacol       Date:  2006-08-29       Impact factor: 4.436

Review 5.  The dynamic kinetochore-microtubule interface.

Authors:  Helder Maiato; Jennifer DeLuca; E D Salmon; William C Earnshaw
Journal:  J Cell Sci       Date:  2004-11-01       Impact factor: 5.285

6.  Interaction of vinblastine with steady-state microtubules in vitro.

Authors:  L Wilson; M A Jordan; A Morse; R L Margolis
Journal:  J Mol Biol       Date:  1982-07-25       Impact factor: 5.469

7.  Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389.

Authors:  Galina Kuznetsov; Murray J Towle; Hongsheng Cheng; Takanori Kawamura; Karen TenDyke; Diana Liu; Yoshito Kishi; Melvin J Yu; Bruce A Littlefield
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

8.  The effects of vinflunine, vinorelbine, and vinblastine on centromere dynamics.

Authors:  Tatiana Okouneva; Bridget T Hill; Leslie Wilson; Mary Ann Jordan
Journal:  Mol Cancer Ther       Date:  2003-05       Impact factor: 6.261

9.  Tension on chromosomes increases the number of kinetochore microtubules but only within limits.

Authors:  J M King; R B Nicklas
Journal:  J Cell Sci       Date:  2000-11       Impact factor: 5.285

10.  Checkpoint signals in grasshopper meiosis are sensitive to microtubule attachment, but tension is still essential.

Authors:  R B Nicklas; J C Waters; E D Salmon; S C Ward
Journal:  J Cell Sci       Date:  2001-12       Impact factor: 5.285

View more
  74 in total

1.  Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancer.

Authors:  Hyman Muss; Javier Cortes; Linda T Vahdat; Fatima Cardoso; Chris Twelves; Jantien Wanders; Corina E Dutcus; Jay Yang; Seth Seegobin; Joyce O'Shaughnessy
Journal:  Oncologist       Date:  2014-03-28

Review 2.  Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent.

Authors:  Nicholas F Dybdal-Hargreaves; April L Risinger; Susan L Mooberry
Journal:  Clin Cancer Res       Date:  2015-04-02       Impact factor: 12.531

Review 3.  Eribulin -- a review of preclinical and clinical studies.

Authors:  Umang Swami; Imran Chaudhary; Mohammad H Ghalib; Sanjay Goel
Journal:  Crit Rev Oncol Hematol       Date:  2011-04-14       Impact factor: 6.312

4.  Enzyme-Catalyzed Intramolecular Enantioselective Hydroalkoxylation.

Authors:  Shu-Shan Gao; Marc Garcia-Borràs; Joyann S Barber; Yang Hai; Abing Duan; Neil K Garg; K N Houk; Yi Tang
Journal:  J Am Chem Soc       Date:  2017-03-01       Impact factor: 15.419

5.  Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients.

Authors:  Rita De Sanctis; Elisa Agostinetto; Giovanna Masci; Emanuela Ferraro; Agnese Losurdo; Alessandro Viganò; Lidija Antunovic; Monica Zuradelli; Rosalba Maria Concetta Torrisi; Armando Santoro
Journal:  Oncology       Date:  2018-07-23       Impact factor: 2.935

6.  Eribulin as a Feasible and Safe Monotherapy in a Dialytic Pretreated Woman with Metastatic Breast Cancer: A Case Report.

Authors:  Raffaele Nettuno; Carmine Menditto
Journal:  Oncology       Date:  2018-07-23       Impact factor: 2.935

7.  Long-Term Response with Eribulin Mesylate in a Breast Cancer Patient: A Case Report.

Authors:  Marta Medici; Emanuela Fossile
Journal:  Oncology       Date:  2018-07-23       Impact factor: 2.935

8.  Eribulin disrupts EB1-microtubule plus-tip complex formation.

Authors:  Brian O'Rourke; Chia-Ping Huang Yang; David Sharp; Susan Band Horwitz
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  Marine antitumor drugs: status, shortfalls and strategies.

Authors:  Ira Bhatnagar; Se-Kwon Kim
Journal:  Mar Drugs       Date:  2010-10-15       Impact factor: 5.118

10.  Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618.

Authors:  Susanne M Arnold; James Moon; Stephen K Williamson; James N Atkins; Sai-Hong I Ou; Michael LeBlanc; Susan G Urba
Journal:  Invest New Drugs       Date:  2009-11-25       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.